Paula Marlton
Overview
Explore the profile of Paula Marlton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
2157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Mulligan S, Opat S, Cheah C, Kuss B, Hertzberg M, Marlton P, et al.
Leuk Lymphoma
. 2022 Nov;
64(2):312-318.
PMID: 36423351
Ibrutinib is a small molecule inhibitor of Bruton's tyrosine kinase indicated for the treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL)....
12.
Mulligan S, Opat S, Marlton P, Kuss B, Gerungan P, Puig A, et al.
Br J Haematol
. 2022 Jun;
198(4):790-793.
PMID: 35702012
No abstract available.
13.
Cull G, Burger J, Opat S, Gottlieb D, Verner E, Trotman J, et al.
Br J Haematol
. 2021 Dec;
196(5):1209-1218.
PMID: 34915592
The phase I/II AU-003 study in patients with treatment-naïve (TN) or relapsed/refractory (R/R) chronic lymphocytic leukaemia/small lymphocytic lymphoma demonstrated that zanubrutinib therapy results in clinically meaningful and durable responses with...
14.
Tam C, Dimopoulos M, Garcia-Sanz R, Trotman J, Opat S, Roberts A, et al.
Blood Adv
. 2021 Nov;
6(4):1296-1308.
PMID: 34724705
Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor evaluated in multiple B-cell malignancy studies. We constructed a pooled safety analysis to better understand zanubrutinib-associated treatment-emergent adverse events (TEAEs) and...
15.
DeAngelo D, Jonas B, Liesveld J, Bixby D, Advani A, Marlton P, et al.
Blood
. 2021 Sep;
139(8):1135-1146.
PMID: 34543383
Uproleselan (GMI-1271) is a novel E-selectin antagonist that disrupts cell survival pathways, enhances chemotherapy response, improves survival in mouse xenograft and syngeneic models, and decreases chemotherapy toxicity in vivo. A...
16.
Critchley C, Fleming J, Nicol D, Marlton P, Ellis M, Devereux L, et al.
Eur J Hum Genet
. 2021 Jan;
29(3):503-511.
PMID: 33479473
Various forms of private investment are considered necessary for the sustainability of biobanks, yet pose significant challenges to public trust. To manage this tension, it is vital to identify the...
17.
Light E, Wiersma M, Dive L, Kerridge I, Lipworth W, Stewart C, et al.
Aust Health Rev
. 2020 Nov;
45(2):214-222.
PMID: 33212000
Objective This study examined the practices and attitudes of Australian biobanks regarding access to samples and data, as well as local and global networking with other biobanks. Methods This was...
18.
Tam C, Opat S, DSa S, Jurczak W, Lee H, Cull G, et al.
Blood
. 2020 Jul;
136(18):2038-2050.
PMID: 32731259
Bruton tyrosine kinase (BTK) inhibition is an effective treatment approach for patients with Waldenström macroglobulinemia (WM). The phase 3 ASPEN study compared the efficacy and safety of ibrutinib, a first-generation...
19.
Trotman J, Opat S, Gottlieb D, Simpson D, Marlton P, Cull G, et al.
Blood
. 2020 Jul;
136(18):2027-2037.
PMID: 32698195
Inhibitors of Bruton's tyrosine kinase (BTK) have established therapeutic activity in patients with Waldenström macroglobulinemia (WM). Zanubrutinib, a potent and selective BTK inhibitor, was evaluated in a phase 1/2 study...
20.
Mohamed A, Collins J, Jiang H, Molendijk J, Stoll T, Torta F, et al.
PLoS One
. 2020 Jan;
15(1):e0227455.
PMID: 31914155
Background: Multiple myeloma (MM) is a hematological malignancy characterized by the clonal expansion of malignant plasma cells. Though durable remissions are possible, MM is considered incurable, with relapse occurring in...